

The Digital Metabolic Liver Disease Accelerator

Partnering in NASH through digital solutions

Approximately 2-6% of people worldwide live with NASH. NASH is the buildup of fat in the liver, and if not managed properly can lead to cardiovascular disease and/or end-stage liver disease, at which point liver damage may be irreversible.

The digital Metabolic Liver Disease Accelerator will support 1-2 digital solutions with up to 100.000 USD to pilot their solutions with Novo Nordisk. We believe there is so much to be explored in this space and are therefore open to working with startups of all sizes, from pre-seed onwards.

The deadline for application is May 15th, 2022

We are committed to driving change in NASH by tackling this urgent and multifaceted global health challenge through innovative medicines and approaches, including new digital solutions.

What are we looking for?

We are looking for digital solutions, within or outside the disease area whose solution that can make a positive impact at any point in the patient journey – exploration in the following areas include: 1. awareness & education, 2. identification & activation, and 3. screening & diagnosis.

[Register and submit your application](#)

Why participate?

- 
Up to 100.000 USD startup funding to test your solution and implement a pilot together with Novo Nordisk
- 
Network connections with players in the local health ecosystems in our focus markets
- 
Mentoring and support from our experts during the pilot implementation, and based on maturity level the required incubation and development
- 
Office space at Health Tech Hub Copenhagen, our partner and the hottest digital healthcare startup location in the city (optional)

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. [novonordisk.com](https://www.novonordisk.com)

[Register and submit your application](#)

The journey

01

The Metabolic Liver Disease Accelerator launch

The challenge is open for startups and scaleups to submit their pitches. The application deadline is May 15th, 2022

02

Shortlist selection

A panel of experts will review the application and select the eight most promising solutions to be presented on pitch day

03

Pitch day

The pitch day will take place June 15th. 1-2 of the presented solutions will be selected to participate in the Digital Metabolic Liver Disease Accelerator

04

Pilot and implementation

The selected startup(s) will be supported by Novo Nordisk experts, and each will receive up to 100.000 USD to pilot their solutions between September 2022 and January 2023 (dates subject to change)

05

Demo day

After months of hard work, the teams will participate in a demo day in February 2023 to showcase their solutions to the wider Novo Nordisk organization